FiercePharmaAsia—Factory expansion, warning for Korean drugmaker, new results in Takeda trial for relugolix and more

6th October 2017 Uncategorised 0

Welcome to this week’s FiercePharmaAsia report, which includes stories on Big Pharma’s expansion in the region, a U.S. regulatory warning for a South Korean drugmaker, new results in Takeda and Myovant’s trial for relugolix to treat uterine fibroids and more.

More: FiercePharmaAsia—Factory expansion, warning for Korean drugmaker, new results in Takeda trial for relugolix and more
Source: fierce